Compare CGEN & GNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEN | GNT |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 126.2M |
| IPO Year | 2000 | N/A |
| Metric | CGEN | GNT |
|---|---|---|
| Price | $1.48 | $7.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 405.6K | 40.9K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | ★ $6,903,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $231.15 | N/A |
| P/E Ratio | ★ N/A | $5.36 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $4.59 |
| 52 Week High | $2.66 | $5.40 |
| Indicator | CGEN | GNT |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 52.56 |
| Support Level | $1.47 | $7.52 |
| Resistance Level | $1.55 | $8.00 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 16.98 | 31.24 |
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.